HUNTLEY, Ill.--(BUSINESS WIRE)--Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market the LONGBOW Titanium Lateral Expandable Spacer System.
“We are thrilled to be releasing a Titanium version of the first to market LONGBOW Expandable Lateral Spacer System which was designed to accomplish previously unmet surgical goals,” said Rich Mueller, Chief Operating Officer for Life Spine. “The spacer is able to achieve up to 12mm of anterior to posterior expansion allowing for a contracted insertion size of 15mm, but once expanded can boast a footprint closer to that of an ALIF spacer as opposed to a traditional lateral spacer.”
The LONGBOW system is available in lengths ranging from 45-60mm, heights from 9mm-15mm, 0° and 7° lordotic options and widths that expand from 15mm-27mm anterior to posterior. LONGBOW can be post-packed after expansion in-situ with up to 11cc of graft to fill the implant and features Life Spine’s proprietary OSSEO-LOC™ Surface Technology. The system is supported by Life Spine’s full portfolio of Lateral solutions including the CENTRIC® Plier Style Retractor System, Lateral Disc Prep Instruments and the SENTRY™ Lateral Plating Systems.
About Life Spine
Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com and/or https://www.micro-invasive.com.